RESOLVING THE LEDGER
RESOLVING THE LEDGER
This is not a single article. It's every outletcovering this one event, gathered in one place — read AIPROPX's summary, see where the sources line up, then open any report at its origin.
By AIPROPX Editorial Desk · Published · Updated
Everything reported about this story, gathered from 3 sources. Read the summary below, then tap any source to open that report.
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.
Summary indexed by AIPROPX from CNBC’s reporting — the full article is one click away. Open at source →
3 outlets are covering this. Resolve the ledger to read what they collectively report — the common thread, in plain terms.
Every report on this story — read the summary of each, then open any at its source. AIPROPX summarizes and links; it never reproduces the original.
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.
Read this report
Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates
Read this reportAn original, deterministic readout — composed only from the computed coverage facts on this page. No interpretation, no rating; figures only.
AIPROPX has consolidated 4 reports from 3 outlets into a single canonical entry on “Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk.” The covered outlets are based across 2 regions — US and Other.
The earliest report in this entry came from CNBC (Aug 5, 2026, 10:45 UTC); the most recent came from CNBC (Aug 5, 2026, 14:35 UTC).
Comparing the wording across sources, 3 named entities are referenced by multiple outlets and the phrase recurring most across the coverage is “eli lilly”.
2 statements are carried by only one outlet within this set and are not echoed by the others.
Every figure above is a direct count of real published articles. AIPROPX indexes and compares the original reporting — it never rewrites, rates, or editorializes — and each publisher’s full article is always one click away.
Generated by AIPROPX from the source counts above. AIPROPX indexes and resolves coverage; the original publishers are credited and linked at origin in every report.
Coverage from 3 independent outlets across 2 regions — each view opens on its own page.
AIPROPX — “Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk” · https://www.aipropx.com/story/5ef8a4a837a01e2780d5e26eb8035863
Other events being covered across multiple sources right now.
FX’s Adaptation of Bret Easton Ellis’ ‘The Shards’ Can’t Be Saved by a Strong Lead Performance: TV Review
6 outletsRecord EV sales drive new car market to seven-year high
3 outletsAnkeny voters to decide on sales tax increase in special election
2 outletsAir India Names New CEO: Former Ethiopian Airlines Boss to Lead Turnaround
27 outletsLeft-wing political outsider wins Democratic Senate primary in Michigan
20 outletsA SpaceX Rocket Will Soon Crash Into the Moon